This first-time-in-human (FTIH) study will evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating
doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants
with advanced solid tumors. In addition, dostarlimab will be given as monotherapy and in
combination with GSK6097608 and with GSK4428859A (EOS884448) in Japanese and Chinese
participants. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the
same compound. In the rest of the document, the drug will be referred to as GSK4428859A
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.